Regenerative Medicine Partnering Terms and Agreements

Regenerative Medicine Partnering Terms and Agreements

The Regenerative Medicine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in regenerative medicine

Deal terms analysis

Partnering agreement structure

Partnering contract documents

Top deals by value

Most active dealmakers

Average deal terms for regenerative medicine and stem cells

The report provides a detailed understanding and analysis of how and why companies enter regenerative medicine and stem cells partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors regenerative medicine and stem cells technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest regenerative medicine and stem cells agreements including cell therapy agreements announced in the healthcare sector.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all regenerative medicine and stem cells partnering deals announced since 2009 including financial terms where available including over 650 links to online deal records as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What are the precise rights granted or optioned?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of regenerative medicine dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst

Chapter 2 provides an overview of the trends in regenerative medicine dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading regenerative medicine deals since 2009. Deals are listed by headline value, signed by big pharma and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 big pharma companies that are active in rgenerative medicine partnering with a brief summary followed by a comprehensive listing of deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive listing of the top 50 biotech pharma companies that are active in rgenerative medicine partnering with a brief summary followed by a comprehensive listing of deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand

Chapter 6 provides a comprehensive and detailed review of regenerative medicine partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc) and specific therapy focus.

Chapter 7 provides a comprehensive and detailed review of all regenerative medicine partnering deals including cell therapy, organ regeneration, stem cells and tissue regeneration signed and announced since 2009. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in regenerative medicine partnering and dealmaking since 2009.

In addition, a comprehensive appendix is provided organized by regenerative medicine partnering company A-Z, deal type and therapy areas. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of regenerative medicine technologies and products.

Regenerative Medicine Partnering Terms and Agreements provides the reader with the following key benefits: